Average weight loss with semaglutide in the STEP trials was approximately 15-20 percent of body weight
Their focus on compounded GLP-1 medications provides cost-effective access to semaglutide and tirzepatide with thorough medical support
Under the MFN framework, Medicare and Medicaid programs are expected to access select GLP-1s at approximately $245 per month, though coverage for weight-loss-only use remains limited or excluded in many states
The extensive preclinical research foundation, favorable preclinical safety profile, and preliminary human experience suggest BPC-157 warrants continued investigation as a potential therapeutic agent for tissue repair and regeneration
Working collaboratively, we can navigate this side effect and maintain a positive body image throughout your weight loss journey
For some people who are particularly vulnerable to sarcopenia, it is important to be cautious when using GLP-1s to avoid too much loss of muscle mass